MIMEDX GROUP, INC. (NASDAQ:MDXG) Files An 8-K Other Events
Item 8.01
On April 26, 2019, the Circuit Court for the Second Judicial Circuit in and for Leon County, Florida ordered MiMedx Group, Inc. (the “Company”) to hold the 2018 annual meeting of the Company’s shareholders (the “2018 Annual Meeting”) on June 17, 2019. The Company plans to appeal the order. However, unless and until the Company makes a public announcement otherwise, the 2018 Annual Meeting will take place on June 17, 2019. In all events, the Company desires to hold the 2018 Annual Meeting at a time when the Company can provide its shareholders with meaningful information so that shareholders would be in a position to act on an informed basis at the 2018 Annual Meeting.
Any shareholder proposals or nominations under the Company’s Amended and Restated Bylaws must be received by the Company on or before May 6, 2019 and otherwise comply with the Company’s Amended and Restated Bylaws. For any proposal to be included in the Company’s proxy statement for the 2018 Annual Meeting to Rule 14a-8 under the Securities Exchange Act of 1934, such proposal must be received by the Company on or before May 6, 2019 and otherwise comply with the requirements of Rule 14a-8.
About MIMEDX GROUP, INC. (NASDAQ:MDXG)
MiMedx Group, Inc. (MiMedx) is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. The Company operates in the Regenerative Biomaterials business segment, which includes the development, processing and marketing of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues in the wound care, surgical, sports medicine, ophthalmic and dental market categories. Its biomaterial platform technologies are AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. The Company processes the human amniotic membrane utilizing its PURION Process, to produce an implant. MiMedx is the supplier of amniotic tissue, having supplied over 500,000 allografts.
